Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Argent BiopharmaRGTLF 3-Year EPS without NRI Growth Rate is 61.40% as of Dec. 2025, which is 262% above its 10-year median of 16.95. The stock has 8 warning signs investors should review. Among 785 Drug Manufacturers companies, Argent Biopharma ranks better than 92.61% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 61.40% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 50.90% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 24.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Argent Biopharma was 75.10% per year. The lowest was -204.60% per year. And the median was 16.95% per year.
Argent Biopharma (OTCPK:RGTLF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Argent Biopharma 3-Year EPS without NRI Growth Rate Related Terms
RGTLF vs ZTS: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Argent Biopharma 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Argent Biopharma's 3-Year EPS without NRI Growth Rate falls into.
Argent Biopharma 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 61.40% mean?
Argent Biopharma (RGTLF) has a 3-Year EPS without NRI Growth Rate of 61.40% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Argent Biopharma and its competitors. This is 262% above median its historical median of 16.95. According to the industry distribution chart, Argent Biopharma ranks #58 out of 785 companies in the Drug Manufacturers industry, placing it in the top 7.4%.
Is Argent Biopharma's 3-Year EPS without NRI Growth Rate too high?
Argent Biopharma's current 3-Year EPS without NRI Growth Rate of 61.40% is 262% above median its 10-year median of 16.95. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.70. Argent Biopharma's value of 61.40% is 533% above this industry median. Based on the distribution chart, Argent Biopharma ranks #58 out of 785 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Argent Biopharma's 3-Year EPS without NRI Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Argent Biopharma ranks #58 out of 785 companies for 3-Year EPS without NRI Growth Rate. This places Argent Biopharma in the top 7% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 9.70. Argent Biopharma's value of 61.40% is 533% above this benchmark. While the company's 10-year median is 16.95 vs. the industry median of 9.70, Argent Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.70, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Argent Biopharma's current 3-Year EPS without NRI Growth Rate of 61.40% is 533% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Argent Biopharma and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Argent Biopharma's current 3-Year EPS without NRI Growth Rate is 61.40%, which is 262% above median its own 10-year median of 16.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argent Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Argent Biopharma (RGTLF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.01 — trading 72.5% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 61.40%, which is 262% above median its 10-year median of 16.95 and 533% above the Drug Manufacturers industry median of 9.70. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Argent Biopharma (RGTLF), the current 3-Year EPS without NRI Growth Rate is 61.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGTLF has been successfully added to your 
